FDA warns of rare ‘eye stroke’ risk from GLP-1 drugs

AI Summary

The U.S. Food and Drug Administration required manufacturers of GLP-1 drugs to warn patients and healthcare providers about a potential increased risk of non-arteritic anterior ischemic optic neuropathy, sometimes called an “eye stroke.” The condition is rare, and the warning applies to drugs used for weight loss and diabetes.

The Food and Drug Administration (FDA) ‌on Monday required pharmaceutical companies to warn patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes.  Non-arteritic anterior ischemic optic neuropathy (NAION), often referred to as an “eye stroke,” is a rare condition…